Download PDF
Thromb Haemost 2008; 99(06): 1040-1048
DOI: 10.1160/TH07-09-0541
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor

Helene F. S. Negaard
1   Departments of Haematology
4   Faculty of Medicine, University of Oslo, Norway
,
Per Ole Iversen
1   Departments of Haematology
4   Faculty of Medicine, University of Oslo, Norway
,
Bjørn Østenstad
2   Oncology, and
,
Nina Iversen
3   Medical Genetics, Ullevål University Hospital Trust, Oslo, Norway
,
Pål A. Holme
5   Department of Haematology, Rikshospitalet UNiversity Hospital Trust, Oslo, Norway
,
Per Morten Sandset
1   Departments of Haematology
4   Faculty of Medicine, University of Oslo, Norway
› Author AffiliationsFinancial support: The study was financially supported with grants from the Norwegian Eastern Health Authority Trust (fellowship for HFSN), Ullevål University Hospital Trust and the University of Oslo, Norway.
Further Information

Publication History

Received 05 September 2007

Accepted after major revision 31 March 2008

Publication Date:
27 November 2017 (online)

    Permissions and Reprints

Summary

Patients with haematological malignancies carry increased risk of venous thrombosis (VT). However, the mechanisms that link these malignancies to activated coagulation have not been fully identified. Since anti-haemostatic agents are studied in clinical trials for their potential to prolong survival in cancer patients, a detailed characterisation of haemostatic markers in cancer subtypes is needed. Hence, in this study, we measured the plasma concentrations and mRNA expression in blood mononuclear cells of haemostatic parameters in 93 patients with haematological neoplasias (acute myeloid leukaemia, chronic lymphatic leukaemia, multiple myeloma, and non-Hodgkin’s lymphoma) before start and after completion of cancer therapy. At diagnosis we found activation of coagulation and fibrinolysis, especially in patients with acute myeloid leukaemia. This hypercoagulation was not associated with increased levels of tissue factor (TF) or factor VII (fVII) antigen or mRNA, or levels of activated fVII. In conclusion we found a hypercoagulable state in patients with haematological malignancy that did not seem to be initiated by TF.

Keywords

Coagulation - leukaemia - lymphoma - myeloma - tissue factor
 

  • References

  • 1 Blom JW, Doggen CJM, Osanto S. et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Asoc 2005; 293: 715-722.
    CrossrefPubMedGoogle Scholar
  • 2 Sorensen HT, Mellemkjaer L, Olsen JH. et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
    CrossrefPubMedGoogle Scholar
  • 3 Pruemer J.. Prevalence, causes, and impact of cancer-associated thrombosis. Am J Health Syst Pharm 2005; 62: S4-S6.
    PubMedGoogle Scholar
  • 4 Caine GJ, Stonelake PS, Lip GYH. et al. The hypercoagulable state of malignancy: Pathogenesis and current debate. Neoplasia 2002; 4: 465-473.
    CrossrefPubMedGoogle Scholar
  • 5 Rickles FR, Patierno SR, Fernandez PM.. Tissue factor, thrombin and cancer. Chest 2003; 124: 58S-68S.
    CrossrefPubMedGoogle Scholar
  • 6 Monroe DM, Hoffman M. What does it take to make the perfect clot?. Arterioscler Thromb Vasc Biol 2006; 26: 41-48.
    CrossrefPubMedGoogle Scholar
  • 7 Semeraro N, Montemurro P, Giordano P. et al. Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma. Thromb Haemost 1994; 72: 54-57.
    PubMedGoogle Scholar
  • 8 Contrino J, Hair G, Kreutzer DL. et al. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209-215.
    CrossrefPubMedGoogle Scholar
  • 9 Nadir Y, Katz T, Sarig G. et al. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor. Haematologia (Budap) 2005; 90: 1549-1556.
    PubMedGoogle Scholar
  • 10 Sase T, Wada H, Yamaguchi M. et al. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost 2005; 93: 153-159.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Zhang Y, Deng Y, Luther T. et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumour cells in mice. J Clin Invest 1994; 94: 1320-1327.
    CrossrefPubMedGoogle Scholar
  • 12 Wang Z, Wang M, Amarzguioui M. et al. Downregulation of Tissue Factor by RNA interferences in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int J Cancer 2004; 112: 994-1002.
    CrossrefPubMedGoogle Scholar
  • 13 Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. The Lancet Oncology 2005; 6: 401-410.
    CrossrefPubMedGoogle Scholar
  • 14 Sanz MA, Jarque I, Martin G. et al. Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 1988; 61: 7-13.
    CrossrefPubMedGoogle Scholar
  • 15 Bennet JM, Catovsky D, Daniel MT. et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report on the French-American-British cooperative Group. Ann Intern Med 1985; 103: 620-625.
    CrossrefPubMedGoogle Scholar
  • 16 Oscier D, Fegan C, Hillmen P. et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004; 125: 294-317.
    CrossrefPubMedGoogle Scholar
  • 17 Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2005; 132: 410-451.
    PubMedGoogle Scholar
  • 18 WHO. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001 .
    PubMedGoogle Scholar
  • 19 Binet JL, Auquier A, Dighiero G. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
    CrossrefPubMedGoogle Scholar
  • 20 Lister TA, Crowther D, Sutcliffe SB. et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
    CrossrefPubMedGoogle Scholar
  • 21 The Norwegian Society of Haematology. National guidelines.. Available at: http://www.legeforeningen.no/index.gan?id=11652&subid=0 Accessed 2004.
    PubMedGoogle Scholar
  • 22 The Norwegian Lymphoma group. National guidelines.. Available at: http://www.legeforeningen.no/index.gan?id=67213 Accessed 2004.
    PubMedGoogle Scholar
  • 23 Cheson BD, Bennett JM, Kopecky KJ. et al. Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649.
    CrossrefPubMedGoogle Scholar
  • 24 Cheson BD, Bennett JM, Grever M. et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
    Google Scholar
  • 25 Cheson BD, Horning SJ, Coiffier B. et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
    CrossrefPubMedGoogle Scholar
  • 26 Taylor FB, Toh CH, Hoots WK. et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-1330.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Kirchgesser M, Adem C, Malmberg W. et al. MagNA Pure LC RNA Isolation Kit – High Performance: Maximum RNA Yield and Quality from Various Samples. Biochemica 2004; 12-13.
    PubMedGoogle Scholar
  • 28 Bendz B, Andersen TO, Sandset PM. A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor Type 1. Thromb Res 2000; 97: 463-472.
    CrossrefPubMedGoogle Scholar
  • 29 Adam M, Vauthier C, Morrissey JH, Woodhams BJ. Assay development for plasma factor VIIa-antithrombin complex (fVIIa-AT). J Thromb Haemost 2007; (Suppl. 02) P-S-111.
    PubMedGoogle Scholar
  • 30 Exner T, Joseph J, Low J. et al. A new activated factor X-based clotting method with improved specificity for procoagulant phospholipid. Blood Coagul Fibrinolysis 2003; 14: 773-779.
    CrossrefPubMedGoogle Scholar
  • 31 Applied Biosystems. Relative quantification of gene expression. ABI Prism 7700 Sequence Detection System. User Bulletin No.2.. 1997 .
    PubMedGoogle Scholar
  • 32 Chojnowski K, Wawrzyniak E, Trelinski J. et al. Assessment of coagulation disorders in patients with acute leukemia before and after cytostatic treatment. Leuk Lymphoma 1999; 36: 77-84.
    CrossrefPubMedGoogle Scholar
  • 33 Sase T, Wada H, Kamikura Y. et al. Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. Thromb Haemost 2004; 92: 132-139.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Rao LV, Rapaport SI, Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 1993; 81: 2600-2607.
    PubMedGoogle Scholar
  • 35 Hair GA, Padula S, Zeff R. et al. Tissue factor expression in human leukemic cells. Leuk Res 1996; 20: 1-11.
    CrossrefPubMedGoogle Scholar
  • 36 Langer F, Amirkhosravi A, Loges S. et al. An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GMCSF. Thromb Haemost 2004; 92: 1136-1146.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 1977; 270: 347-349.
    CrossrefPubMedGoogle Scholar
  • 38 Kamikura Y, Wada H, Sase T. et al. Hemostatic abnormalities and leukocyte activation caused by infection in patients with malignant lymphoma during chemotherapy. Thromb Res 2006; 117: 671-679.
    CrossrefPubMedGoogle Scholar
  • 39 Tanaka M, Yamanishi H. The expression of tissue factor antigen and activity on the surface of leukemic cells. Leuk Res 1993; 17: 103-111.
    CrossrefPubMedGoogle Scholar
  • 40 Carr JM, Dvorak AM, Dvorak HF. Circulating membrane vesicles in leukemic blood. Cancer Res 1985; 45: 5944-5951.
    PubMedGoogle Scholar
  • 41 Lwaleed BA, Cooper AJ, Voegeli D. et al. Tissue factor: A critical role in inflammation and cancer. Biol Res Nurs 2007; 9: 97-107.
    CrossrefPubMedGoogle Scholar
  • 42 Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: Regulation by cytosolic calcium. PNAS 1990; 87: 6995-6999.
    CrossrefPubMedGoogle Scholar
  • 43 Eilertsen KE, Osterud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis 2004; 15: 521-538.
    PubMedGoogle Scholar
  • 44 Sandset PM, Warn-Cramer BJ, Rao VM. et al. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88: 708-712.
    CrossrefPubMedGoogle Scholar
  • 45 Dahm A, Vlieg AH, Bendz B. et al. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 4387-4392.
    CrossrefPubMedGoogle Scholar
  • 46 Radziwon P, Schenk JF, Mazgajska K. et al. Tissue factor (TF) and inhibitor (TFPI) concentrations in patients with urinary tract tumors and haematological malignancies. Pol Merkur Lekarski 2002; 13: 308-311.
    PubMedGoogle Scholar
  • 47 Iversen N, Lindahl AK, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 1998; 102: 889-895.
    CrossrefPubMedGoogle Scholar